Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Han L, Rodriguez E, Shaw C, Kurian J, Capuano S, Escalante GM, Muniraju M, Jung K, Mutsvunguma LZ, Engelman K, Jung J, Ross CN, Reidel IG, Ogembo JG. Newly developed monoclonal antibodies for marmoset immunosuppression enable KSHV lytic replication and salivary shedding: A promising model for KSHV pathogenesis studies. PLoS Pathog. 2026 Oct; 22(10):e1014698.
-
Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Cliff ERS, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N. T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. J Hematol Oncol. 2026 10 07; 19(1).
-
Sciurba FC, Watz H, Bourdin A, Janssens W, Martinez FJ, Zheng J, van den Berge M, Bonini M, Han MK, Singh D, Criner GJ, Brightling CE, Papi A, Bhatt SP, Jenkins M, Mikosz M, Cho?bi?ski P, Ziemiecka M, Löfdahl M, Arya D, Yadavalli M, Brodek BH, Fagerås M, Bardsley S, Martin N, Patel R, Psallidas I. Tozorakimab to Prevent COPD Exacerbations. N Engl J Med. 2026 Oct 29; 395(17):1703-1716.
-
Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood Adv. 2026 08 25; 10(16):5594-5606.
-
Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026 Nov; 40(11):2530-2539.
-
Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Aug; 22(18):2169-2177.
-
Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Apr 28; 10(8):2616-2625.
-
Willsey GG, Rudolph MJ, Piazza CL, Chen Y, Freeman-Gallant G, Cavacini LA, Vance DJ, Mantis NJ. Broadly conserved protective epitopes on the lyme disease vaccine antigen, OspA. PLoS Pathog. 2026 04; 22(4):e1013740.
-
Iacone Y, Zikos J, Foehl D, Katyal P, Gollamudi V, Bibb L, Magnani DM. Development of anti-IgA monoclonal and polyclonal reagents for detecting mucosal and systemic IgA in nonhuman primates. J Immunol Methods. 2026 May; 548:114054.